Drugs / Alrizomadlin
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05701306 | Feb 2023 → Jun 2026 overdue | neuroblastoma | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04275518 | Jul 2020 → Dec 2025 overdue | acute myeloid leukemia, myelodysplastic syndrome | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT02935907 | Oct 2016 → Jun 2019 | — | Ascentage Pharma Group Inc. | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06735820 | Oct 2025 → Oct 2027 expected | atypical neurofibroma, malignant peripheral nerve sheath tumor, neurofibromatosis type 1 | AeRang Kim | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04785196 | May 2021 → Apr 2026 overdue | liposarcoma | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04358393 | Dec 2020 → Dec 2024 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03781986 | Oct 2019 → Jan 2026 overdue | salivary gland cancer | University of Michigan Rogel Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03611868 | Aug 2018 → Dec 2025 overdue | CDK4 linked melanoma, cutaneous melanoma, malignant peripheral nerve sheath tumor, mucosal melanoma +1 | Ascentage Pharma Group Inc. | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06654050 | Mar 2026 | BAP1-related tumor predisposition syndrome, malignant mesothelioma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT04496349 | Jul 2021 → May 2026 overdue | T-cell prolymphocytic leukemia | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alrizomadlin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06654050 ↗ |
| Known as | APG-115 | “Alrizomadlin (APG-115) oral tablets (150 mg) taken every other day on Days 1, 3, 5, 7, 9, 11, and 13 of every cycle (1 cycle=21 days) for 8 cycles (i.e., Course 1).” NCT06654050 ↗ |
| Action | Inhibit | “MDM2) inhibitor” NCT02935907 ↗ |
| Modality | Small molecule | “orally active small-molecule” NCT02935907 ↗ |
| Route | Oral | “Orally Administered APG-115” NCT02935907 ↗ |
| Target | MDM2 | “mouse double minute 2 homolog (MDM2) inhibitor” NCT02935907 ↗ |